TSG Therapeutics Overview

  • Founded
  • 2016
  • Status
  • Private
  • Latest Deal Type
  • Accelerator/​Inc
  • Latest Deal Amount
  • $50K
Latest Deal Amount
  • Investors
  • 1

TSG Therapeutics General Information


Developer of first-in-class antiviral medicines designed to eliminate viral infectious diseases. The company's medicines directly attack viruses through a mechanism that is physically based, rather than enzymatic, and has potential for broad activity against a spectrum of viruses based on virus size and curvature of a lipid envelope, enabling patients to tackle emerging viral threats.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • 7 Straits View Number 05-01
  • Marina One East Tower
  • Singapore, 018936
  • Singapore
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

TSG Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Accelerator/Incubator 19-Dec-2018 $50K 0000 Completed Pre-Clinical Trials
To view TSG Therapeutics’s complete valuation and funding history, request access »

TSG Therapeutics Executive Team (4)

Name Title Board Seat Contact Info
Will Park Co-Founder and Chief Executive Officer
Patricia Fast Ph.D Chief Technology Officer
Cecil Czerkinsky Ph.D Chief Scientific Officer
Nam-Joon Cho Co-Founder
To view TSG Therapeutics’s complete executive team members history, request access »

TSG Therapeutics Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
SparkLabs Group Venture Capital Minority 000 0000 000000 0
To view TSG Therapeutics’s complete investors history, request access »